Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln
02:10am, Friday, 04'th Oct 2024
Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million.
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
04:01pm, Monday, 30'th Sep 2024
Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
05:18pm, Friday, 27'th Sep 2024
Shares of Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) edged higher Friday after their chronic obstructive pulmonary disease (COPD) treatment received approval from the Food and Drug Administrat
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
11:17am, Friday, 27'th Sep 2024
On Friday, the FDA approved Regeneron Pharmaceuticals, Inc. REGN and Sanofi SA's SNY Dupixent (dupilumab) as an add-on maintenance treatment of inadequately controlled chronic obstructive pulmonary
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
09:39am, Friday, 27'th Sep 2024
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies said on Fr
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
09:35am, Friday, 27'th Sep 2024
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlle
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
07:00am, Friday, 27'th Sep 2024
Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two l
Are Investors Undervaluing Sanofi (SNY) Right Now?
10:46am, Thursday, 26'th Sep 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
10:41am, Thursday, 26'th Sep 2024
Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.
Press Release: Availability of the Q3 2024 Aide mémoire
01:30am, Thursday, 26'th Sep 2024
Availability of the Q3 2024 Aide mémoire Paris, France – September 26, 2024. Sanofi announced today that its Q3 2024 Aide mémoire is available on the "Investors" page of the company's website: Thi
Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports
02:18pm, Tuesday, 24'th Sep 2024
Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion) or more, from private equity firms Clayton Dubilier & Rice and PAI Partne
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
02:45pm, Monday, 23'rd Sep 2024
REGN and SNY get positive CHMP opinion on the label expansion of Dupixent in the EU for eosinophilic esophagitis in children down to 1 year of age.
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
11:13am, Monday, 23'rd Sep 2024
On Monday, Sanofi SA SNY agreed to make a $27 million strategic investment in Ventyx Biosciences Inc VTYX.
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
11:01am, Monday, 23'rd Sep 2024
This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
